March 29, 2019

World Allergy Congress Lyon 2019 : Novel therapies in skin allergic diseases.


ANT CONGRES
 
FOCUS ON OUR PLENARY SESSIONS
 
“Novel therapies in skin allergic diseases”
 
Atopic dermatitis (AD) is the most prevalent skin allergy. Not surprisingly, there has been increasing interest in developing experimental approaches to study the pathogenesis of human AD in vivo, in vitro, and in silico to better define pathophysiologic mechanisms and identify novel therapeutic targets and biomarkers that predict therapeutic response. 
 
In a review by Eyerich et al, the authors explore a range of models, including genetic mutations relevant to AD, experimental integration of ‘‘omics’’ data sets, and development of predictive computational models. They note that although no one model captures the complex AD pathophysiology, they show that several do provide insights into key elements of cutaneous biology, molecular pathways, and therapeutic target identification. 
 
Furthermore, recent developments in computational analysis, including application of machine learning and a systems approach to data integration and predictive modeling, highlight the applicability of these methods to AD subclassification (endotyping), therapy development, and precision medicine. 
 
 
READ MORE
 
 
During the WAC 2019 we will look at novel therapies in skin allergic diseases
 
 
 
Audrey NOSBAUM (France) 
 
Small molecules in skin allergic diseases 
 
TO KNOW MORE
 
Marcus MAURER (Germany) 
 
Biologicals in chronic spontaneous urticaria 
 
TO KNOW MORE
 
Thomas BIEBER (Germany) 
 
Biologics in Atopic dermatitis 
 
TO KNOW MORE
 
 
Call for Abstracts ends on May 6, 2019
 
 
SUBMIT TODAY
 
 
Registrations are now open 
 
 
REGISTER TODAY
 
 
VISIT OUR WEBSITE
 
 
Facebook
Twitter
LinkedIn
 
 
 
World Allergy Congress 2019
C/O ANT CONGRES  
 
 

No comments:

Post a Comment